Maraviroc – CAS 376348-65-1

5003500

Maraviroc is provided by Santiago Lab. 

Purity (LC-MS)

99 %

Package contents

Maraviroc

This compound is for research use only. We do not sell to patients.
SizeAvailabilityPriceQuantity
100 mg

In stock

500
1 g

In stock

3500
SKU: N/A Category:

Characterization

CAS: 376348-65-1

IUPAC Name: Cyclohexanecarboxamide, 4, 4-difluoro-N– [(1S) -3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]-

Other names: 4,4-Difluoro-N-[(1S)-3-[(3-exo)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl]cyclohexanecarboxamide, UK 427857, Selzentry, Celsentri

Molecular weight: 513.67  g/mol

Molecular formula: C29H41F2N5O

Description

Maraviroc is an antagonist of the C-C motif chemokine receptor CCR5, which is involved in the cell penetration process by HIV. As a CCR5 receptor antagonist, Maraviroc has a therapeutic application as an antiviral drug for the treatment of HIV infection. Maraviroc is sold under the brand names of Celsentry (EU) or Selzentry (US).

Chemicals are distributed worldwide

Buy Maraviroc now, get your order in 48 hours
  • Shipping through DHL in 48 hours
  • All compounds are safely and rigorously packed

Payment

  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants
References

1. Eneroth, A.; Klasson, B.; Nilsson, M.; Pinho, P.; Samuelsson, B.; Sund, C. Preparation of antiviral nucleotides and their use as HCV polymerase inhibitors. 2012-13693729, US 20130143835, 20121204., 2013.
2. Klasson, B.; Eneroth, A.; Nilsson, M.; Pinho, P.; Samuelsson, B.; Sund, C. Preparation of antiviral nucleotides as HCV polymerase inhibitors. 2012-IB56994, WO 2013084165, 20121205., 2013.
3. Kalayanov, G.; Pinho, P.; Westerlind, H.; Wiktelius, D.; Waehling, H. Preparation of nucleotides as hepatitis C virus polymerase inhibitors. 2014-IB65370, WO 2015056213, 20141016., 2015.
4. Kalayanov, G.; Torssell, S.; Waehling, H. Hepatitis C virus polymerase inhibitors. 2014 SE51005, WO 2015034420, 20140902., 2015.
5. Bethel, R.; Eneroth, A.; Klasson, B.; Oeberg, F. Preparation of dioxolane analogues of uridine for the treatment of cancer. 2015-EP69370, WO 2016030335, 20150824., 2016.